Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy

Mantle cell lymphoma (MCL), an aggressive B-cell malignancy accounting for 6% of non-Hodgkin lymphomas, remains incurable with standard therapy. Despite the approval of bortezomib,[1][1] temsirolimus,[2][2] lenalidomide,[3][3] ibrutinib[4][4] and acalabrutinib,[5][5] patients with relapsed